Jaypirca (Pirtobrutinib)

Jaypirca (pirtobrutinib) is used to treat B‑cell malignancies that rely on BTK signaling.

• Mantle cell lymphoma (MCL): treatment of adult patients with relapsed or refractory disease after at least two prior systemic therapies.
• Chronic lymphocytic leukemia / Small lymphocytic lymphoma (CLL/SLL): therapy for adults whose disease has progressed following prior treatment.
• Relapsed or refractory B‑cell lymphomas: provides an option for patients who have exhausted other BTK inhibitors.
• Other B‑cell malignancies (e.g., marginal zone lymphoma) where BTK inhibition is clinically appropriate.

• Pirtobrutinib binds reversibly to the catalytic site of Bruton’s tyrosine kinase, inhibiting its activity even in the presence of C481 mutations that confer resistance to covalent BTK inhibitors. By blocking BTK, the drug disrupts B‑cell receptor signaling, reducing downstream activation of NF‑κB, MAPK, and AKT pathways, which limits proliferation, survival, and migration of malignant B‑cells.

Adverse reactions reported with pirtobrutinib span a range of frequencies and severities.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Diarrhea: loose stools that may require hydration.
• Nausea: sensation of needing to vomit, often mild.
• Rash: skin eruptions that are usually self‑limited.
• Headache: mild to moderate head discomfort.
• Arthralgia: joint pain without swelling.

Serious or Rare Side Effects

• Hemorrhage: increased risk of bleeding, especially with anticoagulants.
• Atrial fibrillation: irregular heart rhythm that may require cardiology evaluation.
• Severe infections: opportunistic or bacterial infections requiring prompt treatment.
• Cytopenias: significant reductions in blood cell counts (anemia, neutropenia, thrombocytopenia).
• Tumor lysis syndrome: rapid tumor cell breakdown leading to metabolic disturbances.

Key safety considerations for patients receiving Jaypirca include monitoring and risk mitigation strategies.

• Monitor blood counts: regular CBC to detect anemia, neutropenia, or thrombocytopenia.
• Assess bleeding risk: evaluate for concurrent anticoagulants or history of hemorrhage.
• Cardiac evaluation: perform baseline ECG and monitor for atrial fibrillation.
• Avoid strong CYP3A4 inhibitors: dose adjustments may be required if co‑administered.
• Pregnancy and lactation: drug should be used only if potential benefit justifies risk; discuss with specialist.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Pirtobrutinib may interact with other medicines through CYP3A4 metabolism and effects on hemostasis.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase pirtobrutinib exposure.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
• Anticoagulants (e.g., warfarin): heightened bleeding risk.

Moderate Interactions (Monitor Closely)

• Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for bleeding.
• H2 antagonists or proton‑pump inhibitors: may modestly affect absorption.
• Live vaccines: consider timing due to potential immunosuppression.